Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 223

1.

Sketching the prevalence of pharmacogenomic biomarkers among populations for clinical pharmacogenomics.

Patrinos GP.

Eur J Hum Genet. 2019 Sep 4. doi: 10.1038/s41431-019-0499-x. [Epub ahead of print] No abstract available.

PMID:
31485027
2.

Application of Economic Evaluation to Assess Feasibility for Reimbursement of Genomic Testing as Part of Personalized Medicine Interventions.

Simeonidis S, Koutsilieri S, Vozikis A, Cooper DN, Mitropoulou C, Patrinos GP.

Front Pharmacol. 2019 Aug 2;10:830. doi: 10.3389/fphar.2019.00830. eCollection 2019.

3.

Genomic variants in members of the Krüppel-like factor gene family are associated with disease severity and hydroxyurea treatment efficacy in β-hemoglobinopathies patients.

Stratopoulos A, Kolliopoulou A, Karamperis K, John A, Kydonopoulou K, Esftathiou G, Sgourou A, Kourakli A, Vlachaki E, Chalkia P, Theodoridou S, Papadakis MN, Gerou S, Symeonidis A, Katsila T, Ali BR, Papachatzopoulou A, Patrinos GP.

Pharmacogenomics. 2019 Jul;20(11):791-801. doi: 10.2217/pgs-2019-0063. Epub 2019 Aug 8.

PMID:
31393228
4.

Pharmacomicrobiomics informs clinical pharmacogenomics.

Katsila T, Balasopoulou A, Tsagaraki I, Patrinos GP.

Pharmacogenomics. 2019 Jul;20(10):731-739. doi: 10.2217/pgs-2019-0027. Epub 2019 Aug 1.

PMID:
31368841
5.

Educating healthcare providers in the delivery of genomic medicine.

McCarthy J, Patrinos GP.

Per Med. 2019 Jun 13. doi: 10.2217/pme-2019-0025. [Epub ahead of print] No abstract available.

6.

Generic Cost-Effectiveness Models: A Proof of Concept of a Tool for Informed Decision-Making for Public Health Precision Medicine.

Snyder SR, Hao J, Cavallari LH, Geng Z, Elsey A, Johnson JA, Mohamed Z, Chaiyakunapruk N, Chong HY, Dahlui M, Shabaruddin FH, Patrinos GP, Mitropoulou C, Williams MS.

Public Health Genomics. 2018;21(5-6):217-227. doi: 10.1159/000500725. Epub 2019 Jun 12.

PMID:
31189173
7.

Estimating the Effectiveness of DPYD Genotyping in Italian Individuals Suffering from Cancer Based on the Cost of Chemotherapy-Induced Toxicity.

Fragoulakis V, Roncato R, Fratte CD, Ecca F, Bartsakoulia M, Innocenti F, Toffoli G, Cecchin E, Patrinos GP, Mitropoulou C.

Am J Hum Genet. 2019 Jun 6;104(6):1158-1168. doi: 10.1016/j.ajhg.2019.04.017. Epub 2019 May 30.

PMID:
31155283
8.

VKORC1 variants as significant predictors of warfarin dose in Emiratis.

Al-Mahayri ZN, Al Jaibeji HS, Saab Y, Soliman K, Al-Gazali L, Patrinos GP, Ali BR.

Pharmgenomics Pers Med. 2019 Apr 17;12:47-57. doi: 10.2147/PGPM.S187350. eCollection 2019.

9.

Continuous pharmacogenomics and genomic medicine education for healthcare professionals through electronic educational courses.

Tsermpini EE, Stamopoulou T, Kordou Z, Barba E, Siamoglou S, Stathoulias A, Patrinos GP.

Per Med. 2019 May 1;16(3):189-193. doi: 10.2217/pme-2019-0014. Epub 2019 May 21. No abstract available.

PMID:
31109241
10.

A Noninvasive Ocular (Tear) Sampling Method for Genetic Ascertainment of Transgenic Mice and Research Ethics Innovation.

Balafas E, Katsila T, Melissa P, Doulou A, Moltsanidou E, Agapaki A, Patrinos GP, Kostomitsopoulos N.

OMICS. 2019 Jun;23(6):312-317. doi: 10.1089/omi.2019.0057. Epub 2019 May 17.

PMID:
31099704
11.

Role of Genomic Biomarkers in Increasing Fetal Hemoglobin Levels Upon Hydroxyurea Therapy and in β-Thalassemia Intermedia: A Validation Cohort Study.

Kolliopoulou A, Siamoglou S, John A, Sgourou A, Kourakli A, Symeonidis A, Vlachaki E, Chalkia P, Theodoridou S, Ali BR, Katsila T, Patrinos GP, Papachatzopoulou A.

Hemoglobin. 2019 Jan;43(1):27-33. doi: 10.1080/03630269.2019.1597732. Epub 2019 Apr 30.

PMID:
31039620
12.

Integrating Next-Generation Sequencing in the Clinical Pharmacogenomics Workflow.

Giannopoulou E, Katsila T, Mitropoulou C, Tsermpini EE, Patrinos GP.

Front Pharmacol. 2019 Apr 5;10:384. doi: 10.3389/fphar.2019.00384. eCollection 2019. Review.

13.

Optimizing thiopurine dosing based on TPMT and NUDT15 genotypes: It takes two to tango.

Koutsilieri S, Caudle KE, Alzghari SK, Monte AA, Relling MV, Patrinos GP.

Am J Hematol. 2019 Jul;94(7):737-740. doi: 10.1002/ajh.25485. Epub 2019 Apr 10. No abstract available.

PMID:
30945335
14.

Cost-effectiveness analysis of pharmacogenomics-guided clopidogrel treatment in Spanish patients undergoing percutaneous coronary intervention.

Fragoulakis V, Bartsakoulia M, Díaz-Villamarín X, Chalikiopoulou K, Kehagia K, Ramos JGS, Martínez-González LJ, Gkotsi M, Katrali E, Skoufas E, Vozikis A, John A, Ali BR, Wordsworth S, Dávila-Fajardo CL, Katsila T, Patrinos GP, Mitropoulou C.

Pharmacogenomics J. 2019 Jan 16. doi: 10.1038/s41397-019-0069-1. [Epub ahead of print]

PMID:
30647444
15.

Variants in TPMT, ITPA, ABCC4 and ABCB1 Genes As Predictors of 6-mercaptopurine Induced Toxicity in Children with Acute Lymphoblastic Leukemia.

Milosevic G, Kotur N, Krstovski N, Lazic J, Zukic B, Stankovic B, Janic D, Katsila T, Patrinos GP, Pavlovic S, Dokmanovic L.

J Med Biochem. 2018 Jul 1;37(3):320-327. doi: 10.1515/jomb-2017-0060. eCollection 2018 Jul.

16.

New molecular diagnostic trends and biomarkers for amyotrophic lateral sclerosis.

Pampalakis G, Mitropoulos K, Xeromerisiou G, Dardiotis E, Deretzi G, Anagnostouli M, Katsila T, Rentzos M, Patrinos GP.

Hum Mutat. 2019 Apr;40(4):361-373. doi: 10.1002/humu.23697. Epub 2019 Jan 21. Review.

PMID:
30556231
17.

The Role of MicroRNAs in Patients with Amyotrophic Lateral Sclerosis.

Dardiotis E, Aloizou AM, Siokas V, Patrinos GP, Deretzi G, Mitsias P, Aschner M, Tsatsakis A.

J Mol Neurosci. 2018 Dec;66(4):617-628. doi: 10.1007/s12031-018-1204-1. Epub 2018 Nov 10.

PMID:
30415446
18.

Impact of ZBTB7A hypomethylation and expression patterns on treatment response to hydroxyurea.

Chondrou V, Stavrou EF, Markopoulos G, Kouraklis-Symeonidis A, Fotopoulos V, Symeonidis A, Vlachaki E, Chalkia P, Patrinos GP, Papachatzopoulou A, Sgourou A.

Hum Genomics. 2018 Oct 1;12(1):45. doi: 10.1186/s40246-018-0177-z.

19.

Humanome Versus Microbiome: Games of Dominance and Pan-Biosurveillance in the Omics Universe.

Kambouris ME, Gaitanis G, Manoussopoulos Y, Arabatzis M, Kantzanou M, Kostis GD, Velegraki A, Patrinos GP.

OMICS. 2018 Aug;22(8):528-538. doi: 10.1089/omi.2018.0096. Epub 2018 Jul 23.

PMID:
30036141
20.

A note from the editors.

Ginsburg GS, McCarthy JJ, Patrinos GP.

Per Med. 2018 Jul 1;15(4):237-238. doi: 10.2217/pme-2018-0040. Epub 2018 Jun 21. No abstract available.

21.

Searching for Clinically Relevant Biomarkers in Geriatric Oncology.

Katsila T, Patrinos GP, Kardamakis D.

Biomed Res Int. 2018 Feb 18;2018:3793154. doi: 10.1155/2018/3793154. eCollection 2018. Review.

22.

Drug-Induced Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Call for Optimum Patient Stratification and Theranostics via Pharmacogenomics.

Sukasem C, Katsila T, Tempark T, Patrinos GP, Chantratita W.

Annu Rev Genomics Hum Genet. 2018 Aug 31;19:329-353. doi: 10.1146/annurev-genom-083115-022324. Epub 2018 Apr 13. Review.

PMID:
29652519
23.

Genetic Variations Associated with Sleep Disorders in Patients with Schizophrenia: A Systematic Review.

Assimakopoulos K, Karaivazoglou K, Skokou M, Kalogeropoulou M, Kolios P, Gourzis P, Patrinos GP, Tsermpini EE.

Medicines (Basel). 2018 Mar 24;5(2). pii: E27. doi: 10.3390/medicines5020027. Review.

24.

An Exploratory Study of Radiation Dermatitis in Breast Cancer Patients.

Alexopoulou E, Katsila T, Tolia M, Tsoukalas N, Leontsinidis M, Kyrgias G, Kouloulias V, Patrinos GP, Spyropoulou D, Kardamakis D.

Anticancer Res. 2018 Mar;38(3):1615-1622.

PMID:
29491093
25.

The New Age of -omics in Urothelial Cancer - Re-wording Its Diagnosis and Treatment.

Katsila T, Liontos M, Patrinos GP, Bamias A, Kardamakis D.

EBioMedicine. 2018 Feb;28:43-50. doi: 10.1016/j.ebiom.2018.01.044. Epub 2018 Feb 2. Review.

26.

Rebooting Bioresilience: A Multi-OMICS Approach to Tackle Global Catastrophic Biological Risks and Next-Generation Biothreats.

Kambouris ME, Manoussopoulos Y, Kantzanou M, Velegraki A, Gaitanis G, Arabatzis M, Patrinos GP.

OMICS. 2018 Jan;22(1):35-51. doi: 10.1089/omi.2017.0185. Review.

PMID:
29356627
27.

Multi-Omics for Biomarker Discovery and Target Validation in Biofluids for Amyotrophic Lateral Sclerosis Diagnosis.

Mitropoulos K, Katsila T, Patrinos GP, Pampalakis G.

OMICS. 2018 Jan;22(1):52-64. doi: 10.1089/omi.2017.0183. Review.

PMID:
29356625
28.

Genomic variants in the FTO gene are associated with sporadic amyotrophic lateral sclerosis in Greek patients.

Mitropoulos K, Merkouri Papadima E, Xiromerisiou G, Balasopoulou A, Charalampidou K, Galani V, Zafeiri KV, Dardiotis E, Ralli S, Deretzi G, John A, Kydonopoulou K, Papadopoulou E, di Pardo A, Akcimen F, Loizedda A, Dobričić V, Novaković I, Kostić VS, Mizzi C, Peters BA, Basak N, Orrù S, Kiskinis E, Cooper DN, Gerou S, Drmanac R, Bartsakoulia M, Tsermpini EE, Hadjigeorgiou GM, Ali BR, Katsila T, Patrinos GP.

Hum Genomics. 2017 Dec 8;11(1):30. doi: 10.1186/s40246-017-0126-2.

29.

Ten simple rules for international short-term research stays.

Forero DA, Lopez-Leon S, Patrinos GP.

PLoS Comput Biol. 2017 Dec 7;13(12):e1005832. doi: 10.1371/journal.pcbi.1005832. eCollection 2017 Dec. No abstract available.

30.

Recent trends on the role of epigenomics, metabolomics and noncoding RNAs in rationalizing mood stabilizing treatment.

Pisanu C, Katsila T, Patrinos GP, Squassina A.

Pharmacogenomics. 2018 Jan;19(2):129-143. doi: 10.2217/pgs-2017-0111. Epub 2017 Dec 4. Review.

PMID:
29199496
31.

Population pharmacogenomics: impact on public health and drug development.

Patrinos GP.

Pharmacogenomics. 2018 Jan;19(1):3-6. doi: 10.2217/pgs-2017-0166. Epub 2017 Dec 1. No abstract available.

PMID:
29191072
32.

Advancing Global Precision Medicine: An Overview of Genomic Testing and Counseling Services in Malaysia.

Balasopoulou A, Mooy FM, Baker DJ, Mitropoulou C, Skoufas E, Bulgiba A, Katsila T, Patrinos GP.

OMICS. 2017 Dec;21(12):733-740. doi: 10.1089/omi.2017.0136. Epub 2017 Nov 27. Review.

PMID:
29173101
33.

Ashkenazi Jewish genomic variants: integrating data from the Israeli National Genetic Database and gnomAD.

Zlotogora J, Patrinos GP, Meiner V.

Genet Med. 2018 Aug;20(8):867-871. doi: 10.1038/gim.2017.193. Epub 2017 Nov 16.

PMID:
29144512
34.

Genomic Medicine Without Borders: Which Strategies Should Developing Countries Employ to Invest in Precision Medicine? A New "Fast-Second Winner" Strategy.

Mitropoulos K, Cooper DN, Mitropoulou C, Agathos S, Reichardt JKV, Al-Maskari F, Chantratita W, Wonkam A, Dandara C, Katsila T, Lopez-Correa C, Ali BR, Patrinos GP.

OMICS. 2017 Nov;21(11):647-657. doi: 10.1089/omi.2017.0141.

35.

Allele Drop Out Conferred by a Frequent CYP2D6 Genetic Variation For Commonly Used CYP2D6*3 Genotyping Assays.

Scantamburlo G, Tziolia K, Zopf M, Bernardinelli E, Soyal SM, Civello DA, Vanoni S, Dossena S, Patsch W, Patrinos GP, Paulmichl M, Nofziger C.

Cell Physiol Biochem. 2017;43(6):2297-2309. doi: 10.1159/000484380. Epub 2017 Oct 27.

36.

David Bowie and the Art of Slow Innovation: A Fast-Second Winner Strategy for Biotechnology and Precision Medicine Global Development.

Özdemir V, Patrinos GP.

OMICS. 2017 Nov;21(11):633-637. doi: 10.1089/omi.2017.0148. Epub 2017 Oct 24. Review.

PMID:
29064337
37.

Whole transcriptome analysis of human erythropoietic cells during ontogenesis suggests a role of VEGFA gene as modulator of fetal hemoglobin and pharmacogenomic biomarker of treatment response to hydroxyurea in β-type hemoglobinopathy patients.

Chondrou V, Kolovos P, Sgourou A, Kourakli A, Pavlidaki A, Kastrinou V, John A, Symeonidis A, Ali BR, Papachatzopoulou A, Katsila T, Patrinos GP.

Hum Genomics. 2017 Oct 23;11(1):24. doi: 10.1186/s40246-017-0120-8.

38.

Cancer Genomics and Public Health.

Malats N, Katsila T, Patrinos GP.

Public Health Genomics. 2017;20(2):67-69. doi: 10.1159/000479811. Epub 2017 Aug 24. No abstract available.

PMID:
28848209
39.

Sensitive Monogenic Noninvasive Prenatal Diagnosis by Targeted Haplotyping.

Vermeulen C, Geeven G, de Wit E, Verstegen MJAM, Jansen RPM, van Kranenburg M, de Bruijn E, Pulit SL, Kruisselbrink E, Shahsavari Z, Omrani D, Zeinali F, Najmabadi H, Katsila T, Vrettou C, Patrinos GP, Traeger-Synodinos J, Splinter E, Beekman JM, Kheradmand Kia S, Te Meerman GJ, Ploos van Amstel HK, de Laat W.

Am J Hum Genet. 2017 Sep 7;101(3):326-339. doi: 10.1016/j.ajhg.2017.07.012. Epub 2017 Aug 24.

40.

Pharmacometabolomics Informs Quantitative Radiomics for Glioblastoma Diagnostic Innovation.

Katsila T, Matsoukas MT, Patrinos GP, Kardamakis D.

OMICS. 2017 Aug;21(8):429-439. doi: 10.1089/omi.2017.0087. Review.

PMID:
28816643
41.

Exploring public genomics data for population pharmacogenomics.

Lakiotaki K, Kanterakis A, Kartsaki E, Katsila T, Patrinos GP, Potamias G.

PLoS One. 2017 Aug 3;12(8):e0182138. doi: 10.1371/journal.pone.0182138. eCollection 2017.

42.

Exosomes: A Cancer Theranostics Road Map.

Panagiotara A, Markou A, Lianidou ES, Patrinos GP, Katsila T.

Public Health Genomics. 2017;20(2):116-125. doi: 10.1159/000478253. Epub 2017 Jul 20. Review.

43.

Application of the DruGeVar Database in Cancer Genomics and Pharmacogenomics.

Sarris K, Komianou A, Patrinos GP, Katsila T.

Public Health Genomics. 2017;20(2):142-147. doi: 10.1159/000478254. Epub 2017 Jul 14.

PMID:
28704821
44.

Editorial: (Pharmaco)Metabolomics in Drug Discovery and Individualisation of Treatment.

Katsila T, Patrinos GP.

Curr Pharm Des. 2017;23(14):2027. doi: 10.2174/1381612823999170301112648. No abstract available.

PMID:
28701139
45.

When more really means more: WGS standards and quality control.

Patrinos GP.

Hum Mutat. 2017 Aug;38(8):903. doi: 10.1002/humu.23260. No abstract available.

PMID:
28697278
46.

Medical education in pharmacogenomics-results from a survey on pharmacogenetic knowledge in healthcare professionals within the European pharmacogenomics clinical implementation project Ubiquitous Pharmacogenomics (U-PGx).

Just KS, Steffens M, Swen JJ, Patrinos GP, Guchelaar HJ, Stingl JC.

Eur J Clin Pharmacol. 2017 Oct;73(10):1247-1252. doi: 10.1007/s00228-017-2292-5. Epub 2017 Jul 2.

47.

CORRIGENDUM: Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium.

van der Wouden CH, Cambon-Thomsen A, Cecchin E, Cheung KC, Dávila-Fajardo CL, Deneer VH, Dolžan V, Ingelman-Sundberg M, Jönsson S, Karlsson MO, Kriek M, Mitropoulou C, Patrinos GP, Pirmohamed M, Samwald M, Schaeffeler E, Schwab M, Steinberger D, Stingl J, Sunder-Plassmann G, Toffoli G, Turner RM, van Rhenen MH, Swen JJ, Guchelaar HJ; Ubiquitous Pharmacogenomics Consortium.

Clin Pharmacol Ther. 2017 Jul;102(1):152. doi: 10.1002/cpt.725. No abstract available.

PMID:
30239993
48.

Measuring the Value of Pharmacogenomics Evidence.

Patrinos GP, Mitropoulou C.

Clin Pharmacol Ther. 2017 Nov;102(5):739-741. doi: 10.1002/cpt.743. Epub 2017 Jun 5.

PMID:
28581028
49.

Key Pharmacogenomic Considerations for Sickle Cell Disease Patients.

Kolliopoulou A, Stratopoulos A, Siamoglou S, Sgourou A, Ali BR, Papachatzopoulou A, Katsila T, Patrinos GP.

OMICS. 2017 Jun;21(6):314-322. doi: 10.1089/omi.2017.0058. Epub 2017 May 9.

PMID:
28486096
50.

Pharmacogenomics in pediatric acute lymphoblastic leukemia: promises and limitations.

Al-Mahayri ZN, Patrinos GP, Ali BR.

Pharmacogenomics. 2017 May;18(7):687-699. doi: 10.2217/pgs-2017-0005. Epub 2017 May 4. Review.

PMID:
28468529

Supplemental Content

Loading ...
Support Center